
Novo Nordisk's Profit Warnings and Stock Drop Amid Competition and Guidance Cuts
Novo Nordisk's shares plummeted over 22% after the company issued a profit warning due to intense US market competition and slower-than-expected sales growth for its weight-loss drugs Ozempic and Wegovy, leading to a significant reduction in its full-year sales and profit forecasts, amid ongoing legal actions against copycat drugs.










